Selective Adenosine Receptor Modulators for Circadian Rhythm Disorders
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for treating circadian rhythm disorders, such as bright light therapy and melatonin receptor agonists, are not uniformly effective and can have significant side effects, particularly when targeting single adenosine receptor subtypes, which may lead to incomplete synchronization with external environmental rhythms.
Innovation Solution
The use of selective adenosine receptor modulators that target two or three specific adenosine receptor subtypes (A1, A2A, A2B, and/or A3) to modulate the circadian rhythm, utilizing the adenosine signalling pathway to realign the internal biological clock with external environmental cues, thereby enhancing the synchronization and reducing side effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Device complexity
If selective adenosine receptor modulators targeting single receptor subtypes are used, then the treatment mechanism is simplified, but the synchronization effectiveness with external environmental rhythms deteriorates
Solution Approach 1:
The patent combines modulation of multiple adenosine receptor subtypes (A1, A2A, A2B, A3) into a single therapeutic approach. By using modulators that simultaneously target multiple receptor subtypes, the invention achieves more effective circadian rhythm synchronization than single-receptor approaches, while maintaining a relatively simple administration regimen.
2Reliability
If selective adenosine receptor modulators targeting multiple receptor subtypes are used, then the synchronization effectiveness with external environmental rhythms is improved, but the treatment mechanism complexity increases
Solution Approach 1:
The patent employs adenosine receptor modulators that possess multi-functionality by simultaneously acting on multiple receptor subtypes (A1, A2A, A2B, A3). This universal approach allows a single agent to address multiple aspects of circadian rhythm regulation, achieving robust synchronization effectiveness without requiring complex combination therapies.
3Ease of operation
If single adenosine receptor subtype modulation is used, then the treatment is easier to implement, but side effects increase
Solution Approach 1:
The patent applies local quality by selectively modulating specific adenosine receptor subtypes (A1, A2A, A2B, A3) that are specifically involved in circadian rhythm regulation, rather than using non-selective agents. This targeted approach allows effective circadian realignment while minimizing off-target side effects associated with broader receptor modulation.
Data Source
AI summary
The present invention relates to the use of adenosine receptor modulators to affect the circadian rhythm, in particular, to the use of such modulators for the treatment of circadian rhythm disorders. In particular, the invention relates to a composition comprising at least one selective adenosine receptor modulator, wherein said composition modulates two or three, but not all of adenosine receptor subtypes A1, A2A, A2B and/or A3 for use in the treatment of circadian rhythm disorders or for modulating a biological clock.